As part of the university's commitment to economic development and outreach, CTL hosts a variety of events to create connections between the Cornell campuses, industry members, entrepreneurs, and investors.
The Cornell Center for Technology Enterprise and Commercialization (CCTEC) hosted a Mini Startup Boot Camp at the Weill Cornell Medical College campus on February 27, 2013. The event was held in the Weill Greenberg Center, Conference Rooms A, B, and C at 1305 York Avenue. This event is part of CCTEC’s Boot Camp series.
Mini Startup Boot Camp featured a panel of experts who shared their advice on making the pitch. Specifically, they discussed the length of a pitch, how to present, what teams should bring with them, which team member(s) should give the pitch, and what investors are looking for during a pitch. Additionally, attendees learned about legal aspects to consider when starting a company from an experienced attorney. Attendees were able to ask their questions and get answers from experts.
The event culminated with a networking reception. Hors d’oeuvres and drinks were served.
Milena Adamian, M.D., Life Sciences Angel Network
Milena spent the last 20 years on various sides of medical device development. Her career included professional appointments at Interventional Cardiology department of Lenox Hill Hospital (NYC) and Columbus Hospital (Milan, Italy), Medical Director at Boston Scientific Corporation, Equity analyst at Lehman Brothers and Managing Director, Life Sciences, Easton Capital. In her current role of Founder and Executive Director of Life Sciences Angel Network, Milena is focused on the early stage investing and entrepreneurial activities in medical devices and healthcare information technology and education of entrepreneurs and investors. Milena is actively involved in a number of accelerators across the US and continues to be part of Life Science Angels (Palo Alto, CA) and HealthTech Capital (Palo Alto, CA). Milena is an author and a co-author of a number of scientific peer-reviewed papers and a frequent speaker at professional conferences. She is a member of the American College of Cardiology. She holds a M.Sc. degree in Biostatistics and Clinical Research Methods from Mailman School of Public Health at Columbia University, and M.D. and Ph.D. degrees in Clinical Cardiology from Russian Academy of Medical Sciences.
Jon Edelson, M.D., Ascent Biomedical Ventures
Jon is a Venture Partner at Ascent Biomedical Ventures. ABV is located in New York City and invests in early stage life science companies. Jon is also Founder and CEO of a bio-pharmaceutical development company, which is in ABV’s investment portfolio. The company’s lead product was co-invented by Jon, is the subject of an issued patent, and has now been successfully tested in Phase 2 clinical trials. Previously, as CEO, Jon co-founded three venture-backed health care companies. Prior to these companies, Jon served as SVP in sales, marketing, and product development at ValueRx-Value Health, Inc. Prior to ValueRx, Jon, as CEO, founded Medical Decision Resources, Inc. (a drug utilization software and management firm; acquired by ValueRx). Prior to entering business, Jon completed his training in Internal Medicine and conducted clinical research at Harvard’s Brigham & Women’s Hospital and then was a practicing internist in Boston. He attended the Harvard School of Public Health, the University of Chicago’s Pritzker School of Medicine (with honors), and Yale University (summa cum laude). Edelson was also a Dana Scholar at the University of Pennsylvania’s School of Medicine.
Stephen Goodman, Esq., Pryor Cashman LLP
Stephen is co-head of the Mergers and Acquisitions Practice at Pryor Cashman LLP. He has extensive experience representing technology-based companies in public offerings; private placements; limited liability company, partnership and joint venture agreements; and complex arrangements for the acquisition, sale, development and commercialization of patents, copyrights and trademarks, in particular for drug compounds and formulations, software and other technology. He has also written on topics ranging from export controls relating to biotechnology research to raising seed capital for entrepreneurial companies and has lectured on various aspects of pharmaceutical/biotech collaboration agreements. Stephen is a 1977 graduate of New York University School of Law, where he was Order of the Coif and Articles Editor of the Annual Survey of American Law.
Marlene Krauss, M.D., KBL Healthcare Ventures
Marlene was one of the first women to receive an M.B.A. from Harvard Business School and she received an M.D. from Harvard Medical School. She was awarded the Alumni Achievement award at Harvard Business School and was on the Board of Dean’s Advisors. She practiced vitreoretinal surgery and trained at the Beth Israel Deaconess Hospital in medicine and surgery, at Mount Sinai Hospital in New York in ophthalmology and at New York Hospital in vitreoretinal surgery. Marlene combined her expertise in both medicine and business to found KBL Healthcare Ventures, a venture capital firm investing in early stage medical devices, healthcare services and pharmaceuticals. She was a founding investor and Director of Summit Technologies, the first company to develop and commercialize lasers to perform refractive surgery, a procedure that is now known as Lasik. Summit was sold to Bausch & Lomb. She was the founding investor in Candela Laser, which invented and commercialized pioneering lasers in the field of dermatology. She wrote the initial business plan and provided the funding for Lumenos of which she was Chairperson. Lumenos was one of the initial companies to develop the consumer driven healthcare insurance model which is now incorporated in major insurance plans offering high deductible/HSA insurance. Lumenos was sold to Wellpoint. She has invested in and/or founded over 40 healthcare companies, many at the start up stage, and has been a member of the Board of Directors of many of these companies.
Alan Paau, Ph.D., Cornell Center for Technology Enterprise & Commercialization
Alan is responsible for the strategic management of all technologies and intellectual property that arise from the research activities at Cornell University - both at the Weill Medical College in New York City and at the campus in Ithaca. Prior to joining Cornell in January 2007, Paau for nine years was Director and Assistant Vice Chancellor for Technology Transfer and Intellectual Property Services at the University of California, San Diego (San Diego, CA). From 1994 to 1998, he was Executive Director of the Iowa State University Research Foundation, Inc., and Director of Intellectual Property and Technology Transfer at Iowa State University (Ames, IA). Until 1994, he was Associate Director of the Biotechnology Center at the Ohio State University Columbus, OH) with responsibilities in research, teaching, research administration, technology management, and industry liaison. He holds a Ph.D. degree in Biological Sciences and an M.B.A. He also attended briefly the Drake University School of Law. Alan is the inventor to eight US patents and has contributed 30 peer-reviewed research articles to scientific journals and six invited reviews and chapters to technical books.
Josh Wolfe, B.S., Lux Capital
Josh is a Co-Founder and Managing Partner of Lux Capital Management focusing on investments in the physical and life sciences. Josh manages Lux's investments in Nanosys, Cambrios, Siluria and serves on the Board of Directors of Kurion, Silicon Clocks, Crystal IS and Lux Research. Before forming Lux Capital, he worked in Salomon Smith Barney's Investment Banking group, in capital markets at Merrill Lynch on its Financial Futures & Options/Government Strategy desk and at Prudential Securities in Municipal Finance. Prior to venturing into the financial world, Josh published cutting-edge AIDS-immunopathology research in Cell Vision and The Journal of Leukocyte Biology. Josh is a columnist with Forbes, Editor for the Forbes/Wolfe Emerging Tech Report and host of a show on the Forbes Video Network. He has been an invited guest to the White House and Capitol Hill to advise on nanotechnology and emerging technologies, a lecturer at MIT, Harvard, Yale, Cornell, Columbia and NYU, and a frequent guest on CNBC and CNN. Josh graduated from Cornell University with a B.S. in Economics and Finance.
To view photos from the event, click here.